{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:39:22Z","timestamp":1760985562350,"version":"3.41.0"},"reference-count":30,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1999,9]]},"abstract":"<jats:p>PURPOSE: Cytarabine (ara-C) is one of the most effective chemotherapeutic agents in patients with acute leukemia (AL), with a clear dose effect. Use of high-dose ara-C is hampered, however, by a noticeable toxicity, particularly to the CNS. We investigated the usefulness of CNS perfusion imaging with technetium-99m (<jats:sup>99m<\/jats:sup>Tc)-hexamethyl-propylene-amine oxime (HMPAO) single-photon emission computed tomography (SPECT) concurrent to magnetic resonance imaging (MRI) to specifically assess the effects of standard- and high-dose ara-C in children with AL.<\/jats:p><jats:p>PATIENTS AND METHODS: Twenty-six perfusion studies using<jats:sup>99m<\/jats:sup>Tc-HMPAO SPECT were performed in 12 children (age range, 4 to 15 years) with AL after induction therapy, which consisted of a standard-dose ara-C, immediately after consolidation with high-dose ara-C, and later during follow-up (range, 6 to 44 months). The chemotherapy-related adverse events were monitored and correlated to SPECT and MRI.<\/jats:p><jats:p>RESULTS: After the induction phase, all children were neurologically normal on MRI. On SPECT imaging, four children displayed a slightly heterogeneous perfusion. After high-dose ara-C (4 to 36 g\/m<jats:sup>2<\/jats:sup>), five children had regressive neurologic signs of potential toxic origin. Of these five children, only one had an abnormal MRI scan, whereas all patients showed evidence of diffuse cerebral and\/or cerebellar heterogeneous perfusion on SPECT. The seven other patients without any neurologic symptoms had normal MRI scans; SPECT was normal for three patients and abnormal for four patients. On follow-up, for four children who had presented with clinical neurologic toxicity, SPECT improved in three patients and remained unchanged in one patients. In two of these four children, delayed abnormalities (T2 white matter hypersignal and cerebellar atrophy) appeared on MRI scans.<\/jats:p><jats:p>CONCLUSION: In our series, diffuse heterogeneous brain hypoperfusion is often the sole early objective imaging feature identified by SPECT of high-dose ara-C neurotoxicity, where MRI still demonstrates normal pictures.<\/jats:p>","DOI":"10.1200\/jco.1999.17.9.2804","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:05:40Z","timestamp":1487916340000},"page":"2804-2804","source":"Crossref","is-referenced-by-count":25,"title":["Contribution of Single-Photon Emission Computed Tomography in the Diagnosis and Follow-Up of CNS Toxicity of a Cytarabine-Containing Regimen in Pediatric Leukemia"],"prefix":"10.1200","volume":"17","author":[{"given":"Pierre","family":"V\u00e9ra","sequence":"first","affiliation":[{"name":"From the Department of Nuclear Medicine, Charles Nicolle University Hospital, Henri Becquerel Center, Rouen; Departments of Pediatric Hematology and Radiology, Robert Debr\u00e9 Hospital, Paris; and Department of Nuclear Medicine, Beaujon Hospital, Clichy, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Rohrlich","sequence":"additional","affiliation":[{"name":"From the Department of Nuclear Medicine, Charles Nicolle University Hospital, Henri Becquerel Center, Rouen; Departments of Pediatric Hematology and Radiology, Robert Debr\u00e9 Hospital, Paris; and Department of Nuclear Medicine, Beaujon Hospital, Clichy, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Louis","family":"Sti\u00e9venart","sequence":"additional","affiliation":[{"name":"From the Department of Nuclear Medicine, Charles Nicolle University Hospital, Henri Becquerel Center, Rouen; Departments of Pediatric Hematology and Radiology, Robert Debr\u00e9 Hospital, Paris; and Department of Nuclear Medicine, Beaujon Hospital, Clichy, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique","family":"Elmaleh","sequence":"additional","affiliation":[{"name":"From the Department of Nuclear Medicine, Charles Nicolle University Hospital, Henri Becquerel Center, Rouen; Departments of Pediatric Hematology and Radiology, Robert Debr\u00e9 Hospital, Paris; and Department of Nuclear Medicine, Beaujon Hospital, Clichy, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Duval","sequence":"additional","affiliation":[{"name":"From the Department of Nuclear Medicine, Charles Nicolle University Hospital, Henri Becquerel Center, Rouen; Departments of Pediatric Hematology and Radiology, Robert Debr\u00e9 Hospital, Paris; and Department of Nuclear Medicine, Beaujon Hospital, Clichy, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Bonnin","sequence":"additional","affiliation":[{"name":"From the Department of Nuclear Medicine, Charles Nicolle University Hospital, Henri Becquerel Center, Rouen; Departments of Pediatric Hematology and Radiology, Robert Debr\u00e9 Hospital, Paris; and Department of Nuclear Medicine, Beaujon Hospital, Clichy, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Bok","sequence":"additional","affiliation":[{"name":"From the Department of Nuclear Medicine, Charles Nicolle University Hospital, Henri Becquerel Center, Rouen; Departments of Pediatric Hematology and Radiology, Robert Debr\u00e9 Hospital, Paris; and Department of Nuclear Medicine, Beaujon Hospital, Clichy, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Vilmer","sequence":"additional","affiliation":[{"name":"From the Department of Nuclear Medicine, Charles Nicolle University Hospital, Henri Becquerel Center, Rouen; Departments of Pediatric Hematology and Radiology, Robert Debr\u00e9 Hospital, Paris; and Department of Nuclear Medicine, Beaujon Hospital, Clichy, France."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-2804","unstructured":"Russel JA, Powles RL: Neuropathy due to cytosine arabinoside. Br Med J 44:1189,1974-1193,"},{"key":"R2-2804","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197810)42:4<1747::AID-CNCR2820420413>3.0.CO;2-T"},{"key":"R3-2804","doi-asserted-by":"crossref","unstructured":"Rudnik SA, Cadman EC, Capizzi RL, et al: High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer 44:1193,1979-1979,","DOI":"10.1002\/1097-0142(197910)44:4<1189::AID-CNCR2820440404>3.0.CO;2-O"},{"key":"R4-2804","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-87-6-691"},{"key":"R5-2804","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1980.00330150139034"},{"key":"R6-2804","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.4.679"},{"key":"R7-2804","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.4.571"},{"key":"R8-2804","doi-asserted-by":"crossref","unstructured":"Damon LE, Mass R, Linker CA: The association between high-dose cytarabine neurotoxicity and renal insufficiency. J Clin Oncol 10:1563,1989-1568,","DOI":"10.1200\/JCO.1989.7.10.1563"},{"key":"R9-2804","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.6.948"},{"key":"R10-2804","unstructured":"Vaughn DJ, Jarvik JG, Hackney D, et al: High-dose cytarabine neurotoxicity: MR findings during the acute phase. AJNR 14:1014,1993-1016,"},{"key":"R11-2804","unstructured":"Lill DW, Mountz JM, Darji JT: Technetium-99m-HMPAO brain SPECT evaluation of neurotoxicity due to manganese toxicity. J Nucl Med 35:863,1994-866,"},{"key":"R12-2804","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050104"},{"key":"R13-2804","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(94)70212-8"},{"key":"R14-2804","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199701000-00004"},{"key":"R15-2804","doi-asserted-by":"publisher","DOI":"10.1007\/s003810050138"},{"key":"R16-2804","doi-asserted-by":"publisher","DOI":"10.1007\/BF00811439"},{"key":"R17-2804","doi-asserted-by":"publisher","DOI":"10.1007\/BF01084359"},{"key":"R18-2804","doi-asserted-by":"crossref","unstructured":"Harila-Saari AH, Ahonen AKA, Vainionp\u00e4\u00e4 LK, et al: Brain perfusion after treatment of childhood acute lymphoblastic leukemia. J Nucl Med 38:82,1997-88,","DOI":"10.1002\/(SICI)1097-0142(19980101)82:1<200::AID-CNCR25>3.0.CO;2-5"},{"key":"R19-2804","unstructured":"Sti\u00e9venart JL, V\u00e9ra P, Verstichel P, et al: Neurological applications of single photon emission tomography. Rev Neurol (Paris) 151:619,1995-633,"},{"key":"R20-2804","unstructured":"Rowe CC, Berkovic SF, Austin MC, et al: Patterns of post-ictal cerebral blood flow in temporal lobe epilepsy: Qualitative and quantitative analysis. Neurology 26:268,1991-278,"},{"key":"R21-2804","unstructured":"V\u00e9ra P, Kaminska A, Cieuta C, et al: Optimizing the localization of seizure foci in children using subtraction ictal SPECT co-registered to MRI. J Nucl Med 40:786,1999-792,"},{"key":"R22-2804","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870715)60:2<165::AID-CNCR2820600207>3.0.CO;2-G"},{"key":"R23-2804","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830201)51:3<426::AID-CNCR2820510312>3.0.CO;2-S"},{"key":"R24-2804","unstructured":"Barnett MD, Richard MA, Ganesan TS, et al: Central nervous system toxicity of high dose cytosine arabinoside. Semin Oncol 2:227,1985-232, (suppl)"},{"key":"R25-2804","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19811215)48:12<2577::AID-CNCR2820481207>3.0.CO;2-Z"},{"key":"R26-2804","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.35.10.1475"},{"key":"R27-2804","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410140505"},{"key":"R28-2804","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.6.927"},{"key":"R29-2804","doi-asserted-by":"crossref","unstructured":"Sylvester RK, Fisher AJ, Lobell M: Cytarabine-induced cerebellar syndrome: Case report and literature review. Drug Intell Clin Pharm 21:177,1987-180,","DOI":"10.1177\/106002808702100205"},{"key":"R30-2804","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950110408"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1999.17.9.2804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T17:07:38Z","timestamp":1750007258000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1999.17.9.2804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[1999,9]]}},"alternative-id":["10.1200\/JCO.1999.17.9.2804"],"URL":"https:\/\/doi.org\/10.1200\/jco.1999.17.9.2804","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"type":"print","value":"0732-183X"},{"type":"electronic","value":"1527-7755"}],"subject":[],"published":{"date-parts":[[1999,9]]}}}